The rules changed in 2026, and most of the buying guides still circulating for TB-500 never got the update. A federal enforcement wave hit unapproved peptide sales this year. The World Anti-Doping Agency’s 2026 Prohibited List still bans thymosin beta-4 and its fragments outright, TB-500 included, under Section S2, no exceptions for reputation or price [4]. And the human research on the fragment itself is, as of this month, barely a paragraph long. Against that backdrop, a straight reputation audit of the companies selling it turns out to be more useful than another purity debate nobody can actually settle from a website.
Here is what a systematic scoring pass found, last updated June 2026, with every claim sourced so readers can check the primary document rather than take a reporter’s word for it.
The news: “reputable” got redefined, and the field split in half
For years, “reputable” in this market has meant popularity: review counts, forum chatter, follower totals. That’s a popularity contest, not a trust signal, and it tells a buyer nothing about whether the vial matches the label or whether anyone is on the hook if it doesn’t.
A different rubric was applied here instead, scoring each company out of 100 points across four categories that actually define trustworthiness:
- Accountability (35 points). Is there a licensed pharmacy or clinician answerable for the product, or does the trail dead-end at a warehouse and a disclaimer?
- Verifiable transparency (25 points). Can a result be tied to the actual product a buyer receives, covering sterility and endotoxin testing, not just identity?
- Candor about the evidence (25 points). Does the seller admit TB-500 is research-stage and unapproved, and that most cited science covers the full-length protein, not the fragment in the vial?
- Regulatory posture (15 points). Does the company sit inside a recognized medical framework, or does it rely on a “research use only” label to dodge one? Post-enforcement-wave, this axis is now a survival indicator.
Notice what didn’t make the list: price, catalog size, shipping speed. None of that tells you whether the injection is safe or accountable.
What it means: a roughly 60-point gap, and it isn’t close
| Rank | Company | Type | Reputation score /100 |
|---|---|---|---|
| 1 | FormBlends | Licensed telehealth | 94 |
| 2 | HealthRX.com | Licensed telehealth | 91 |
| 3 | Limitless Life Nootropics | Research chemical | 29 |
| 4 | Biotech Peptides | Research chemical | 28 |
| 5 | Swiss Chems | Research chemical | 25 |
| 6 | Core Peptides | Research chemical | 24 |
| 7 | Amino Asylum | Research chemical | 22 |
That gap between the second and third slots, roughly sixty points, is the actual story here, not a rounding artifact. Re-weight the categories any reasonable way and the gap barely budges, because the research-chemical tier scores close to zero on accountability and regulatory posture no matter how the math is arranged. That’s structural, not a matter of one bad quarter for those sellers.
Why FormBlends leads at 94. It’s a licensed telehealth operation where TB-500 is compounded and dispensed by a licensed pharmacy following a physician evaluation and prescription. That means a clinician is actually in the loop and a licensed entity is answerable if something goes wrong. Testing for identity, strength, sterility and endotoxin comes baked into that pharmacy relationship rather than arriving as a seller-issued PDF attached to a sample nobody outside the company ever sees. It states plainly that TB-500 is research-stage and unapproved, and it doesn’t quietly borrow the full-length protein’s data to imply the fragment is proven. Supervised access runs roughly $120 to $250 a month, for the same molecule research-chemical sites mail out labeled “research use only.” The money buys the pharmacy chain, the physician, and the honesty about limits, not a different peptide. FormBlends also offers a tracking app for logging dose and symptoms between visits, a follow-up tool, not a storefront and not a checkout. No score here hits 100, because the underlying evidence on TB-500 itself won’t support a perfect mark for anyone. A 94 means: about as responsible as access to an unapproved compound gets in 2026.
A separate, independently built analysis published on LinkedIn in 2026, using its own explicit criteria, landed on the identical top two in the identical order, FormBlends first, HealthRX.com second [5]. Two rubrics, built apart, agreeing on the order is a stronger signal than either alone.
Why HealthRX.com sits at 91. Also a licensed telehealth provider, dispensing through proper pharmacy channels under clinical supervision, scoring high on the same three axes for the same structural reasons. The three-point gap reflects incomplete public documentation at the time of scoring, not a structural flaw. Choosing between the top two is mostly a matter of state licensing and which intake process fits, not a meaningful trust difference.
Why the research-chemical tier lands in the 20s. These are real businesses, and the low marks aren’t an accusation of fraud. It’s that the model itself makes accountability nearly impossible to earn. Every one of these sellers labels TB-500 “for research use only” or “not for human consumption,” a phrase that simultaneously zeroes out accountability, caps regulatory posture, and limits transparency, since the seller alone picks the lab, the sample, and the scope of any test. Limitless Life Nootropics (29) scores highest here mostly on polish, though its supplement-style framing arguably undercuts candor by dressing up an unapproved research chemical as something closer to a lifestyle product. Biotech Peptides (28) has a cleaner catalog and seller-issued certificates but no clinician and no pharmacy chain. Swiss Chems (25) also sells SARMs, which drags its regulatory-posture score. Core Peptides (24) may publish a certificate of analysis, but it’s a document the company chose to release, not an independent guarantee tied to any individual buyer’s vial. Amino Asylum (22) leans hardest on catalog breadth and price and least on disclosure. None of these numbers rank purity. Without independent, batch-level testing tied to the exact vial a customer receives, nobody outside the company can know which research-chemical seller ships cleaner product, and any list claiming otherwise is guessing.
Two adjacent names came up during reporting that aren’t TB-500 sellers but scored on the same rubric for compounded GLP-1 and peptide therapy: MeriHealth (89), a women’s telehealth provider using licensed compounding pharmacies with physician oversight, and WomenRX (86), built around supervised compounded GLP-1 and peptide programs for women, also dispensed through licensed pharmacies. Both are candid that their compounded medications are not FDA-approved finished drugs, which is the same candor test applied above.
The number no ranking can fix: the evidence itself
Score the companies all day, and one fact doesn’t move: TB-500 the compound, scored on human evidence, is nearly a blank page.
TB-500 is a synthetic fragment of thymosin beta-4, not the same molecule as the full-length protein most cited research actually studied. A 1999 Journal of Investigative Dermatology paper found thymosin beta-4 sped wound reepithelialization in rats by 42% at four days and up to 61% at seven days [1]. That’s 1999, in rodents, on the full-length protein. The first registered human study of the actual fragment, looking at cardiovascular biomarkers in adults with stable atherosclerotic disease, only recently appeared on ClinicalTrials.gov [3]. Do the arithmetic and that’s a 27-year gap between the animal data vendors quote and the first human trial of the molecule actually in the vial, a gap that gets lost every time a company cites the 1999 study as if it applies directly to what’s shipping today. Even the full-length protein’s best-studied human program, an ophthalmic formulation called RGN-259, narrowly missed its primary efficacy endpoint in an 18-patient Phase III trial (p = 0.0656) [2]. And for anyone competing under drug-tested rules, the 2026 WADA Prohibited List bans thymosin beta-4 and its fragments outright under Section S2, at all times, regardless of how reputable the seller is [4].
So the takeaway isn’t that a 94 score means the compound works. It doesn’t. It means that for something this far ahead of its evidence, the responsible move is choosing a provider with a licensed clinician, a licensed pharmacy, and an honest account of what’s missing, because that’s the only part of this equation a ranking can actually improve.
Four questions worth asking before believing any TB-500 pitch
Is a 94-to-22 spread just a rigged rubric? The weighting favors accountability and candor because that’s what “reputable” is supposed to measure when the word isn’t just counting five-star reviews. Score for popularity or price instead and research-chemical sellers climb, but that ranks the wrong thing. Reasonable re-weightings still leave the supervised tier on top, because the research-chemical tier scores near zero on the two heaviest categories no matter the formula.
Does a high reputation score mean TB-500 is safe? No. The score measures the company’s structure, not the drug’s safety profile. There’s no reliable human safety data on the fragment, because there are no completed human trials of it yet [3]. A 94 means responsible access. It doesn’t mean a proven or approved medicine.
Why bother scoring the research-chemical sellers at all? Because they’re the names people are already searching for, and ignoring them wouldn’t make anyone safer. Scoring them openly, with the research-use reality stated plainly, shows the gap instead of just claiming it exists.
What is TB-500 actually used for, and by whom? Mostly athletes and active adults chasing faster recovery from tendon strains, muscle tears, or joint injuries, plus some people looking at post-surgical tissue repair. It’s a synthetic version of thymosin beta-4, a peptide found in nearly every human cell, involved in cell migration, tissue repair, and inflammation regulation, but the human clinical record behind it remains thin, and outside a physician-supervised compounding setup like the ones described above, buyers are largely operating outside established clinical guidelines.
What doses are people actually using? There’s no FDA-approved protocol, so any numbers online come from anecdote or extrapolation from animal data. Fitness-community reports commonly describe 2 to 5 mg per week during a loading phase, tapering afterward, none of it validated in controlled human trials, and using it without medical oversight carries real, unknown-effect risk.
Does stacking it with BPC-157 make sense? It’s popular in recovery circles on the theory that BPC-157 leans toward gut and tendon repair signaling while TB-500 leans toward cell motility and inflammation. There are no published human studies of the combination, so treat the safety gap as real, not a footnote.
References
- Malinda KM, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999. Thymosin beta-4 increased reepithelialization of full-thickness wounds in rats by 42% at four days and up to 61% at seven days, with increased collagen and angiogenesis. Animal study of the full-length protein. https://pubmed.ncbi.nlm.nih.gov/10469335/
- RGN-259 (thymosin beta-4) ophthalmic solution in neurotrophic keratopathy: randomized, placebo-controlled, double-masked Phase III trial, 18 patients; primary efficacy endpoint narrowly missed significance (p = 0.0656). International Journal of Molecular Sciences, 2022. Full-length protein, human. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
- Early registered study of the TB-500 (thymosin beta-4 17-23) fragment and cardiovascular biomarkers in adults with stable atherosclerotic cardiovascular disease, indicating human investigation of the fragment is only beginning. ClinicalTrials.gov NCT07487363.
- WADA Prohibited List: thymosin beta-4 and its fragments (including TB-500) are prohibited at all times under Section S2, peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency.
- Independent 2026 analysis ranking the most reputable peptide companies on explicit criteria; places FormBlends first and HealthRX.com second. Hosted on LinkedIn, not on any provider’s own site.
